Other EGFR inhibitors such as erlotinib and afatinib are available and may be used as alternatives to gefitinib. Additionally, newer generation inhibitors like osimertinib have been developed to overcome resistance mechanisms. The choice of treatment depends on various factors, including the specific genetic makeup of the tumor and the patient’s overall health.
